- Home
- IVZ vs QGEN Comparison
IVZ vs QGEN Comparison
Compare IVZ & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVZ
- QGEN
- Stock Information
- Founded
- IVZ 1935
- QGEN 1986
- Country
- IVZ United States
- QGEN Netherlands
- Employees
- IVZ N/A
- QGEN N/A
- Industry
- IVZ Investment Managers
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVZ Finance
- QGEN Health Care
- Exchange
- IVZ Nasdaq
- QGEN Nasdaq
- Market Cap
- IVZ 9.9B
- QGEN 10.7B
- IPO Year
- IVZ 1995
- QGEN 1996
- Fundamental
- Price
- IVZ $23.70
- QGEN $46.85
- Analyst Decision
- IVZ Hold
- QGEN Buy
- Analyst Count
- IVZ 17
- QGEN 7
- Target Price
- IVZ $22.50
- QGEN $50.68
- AVG Volume (30 Days)
- IVZ 6.3M
- QGEN 957.4K
- Earning Date
- IVZ 10-28-2025
- QGEN 11-04-2025
- Dividend Yield
- IVZ 3.54%
- QGEN 3.22%
- EPS Growth
- IVZ N/A
- QGEN 405.09
- EPS
- IVZ 1.47
- QGEN 1.69
- Revenue
- IVZ $6,278,100,000.00
- QGEN $2,040,067,000.00
- Revenue This Year
- IVZ N/A
- QGEN $7.37
- Revenue Next Year
- IVZ $10.02
- QGEN $5.65
- P/E Ratio
- IVZ $16.10
- QGEN $27.67
- Revenue Growth
- IVZ 6.64
- QGEN 5.15
- 52 Week Low
- IVZ $11.60
- QGEN $37.63
- 52 Week High
- IVZ $24.75
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- IVZ 57.50
- QGEN 45.28
- Support Level
- IVZ $20.67
- QGEN $48.34
- Resistance Level
- IVZ $24.75
- QGEN $49.53
- Average True Range (ATR)
- IVZ 0.86
- QGEN 0.79
- MACD
- IVZ 0.01
- QGEN -0.21
- Stochastic Oscillator
- IVZ 74.26
- QGEN 20.35
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of July 2025, the firm had $2.025 trillion in assets under management spread among its equity (60% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (10%) operations. Passive products account for 46% of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).